2020 American Transplant Congress
Outcomes of Acute Allograft Rejection Treatment with R Anti-Thymocyte Globulin (r-ATG) One Year Post Kidney Transplant
Indiana University School of Medicine, Indianapolis, IN
*Purpose: Acute allograft rejection is considered one of the major causes of renal allograft dysfunction. Despite maximal anti-rejection therapy grafts may not regain baseline function.…2020 American Transplant Congress
Anti-Thymocyte Globulins Induced Immunomodulatory Effect and Increased Regulatory T Cell in a In Vitro Model of Allogeneic Cell Coculture
*Purpose: Two types of Anti-Thymocyte Globulins (ATG) are commonly used in renal transplantation (Thymoglobuline and Grafalon) and induce severe, dose-dependent and sometimes persistent CD4+ T…2020 American Transplant Congress
Carfilzomib-Based Desensitization: Effects on HLA, Non-HLA, Auto, and Antiviral Antibodies
1U Cincinnati, Cincinnati, OH, 2U Cincinnati, Christ Hospital, Cincinnati, OH
*Purpose: An important question in plasma cell (PC) therapies is the specificity of therapy for PC populations. It is known that plasmablast populations are exquisitely…2020 American Transplant Congress
Thymoglobulin Dose and Incidence of Biopsy Proven Acute Rejections in the Early Post Transplant Period
University of Pittsburgh Medical Center, Pittsburgh, PA
*Purpose: Optimal dosing of thymoglobulin (ATG) for induction has not been well defined. Our protocol aims for 5-6mg/kg cumulative dose divided over 4 doses. However,…2020 American Transplant Congress
Short Term Outcomes in Kidney Transplant Patients Receiving De Novo Belatacept with Anti-Thymocyte Globulin Induction
Pharmacy, Jackson Memorial Hospital, Miami, FL
*Purpose: Mainstay immunosuppressive therapy after kidney transplant is a calcineurin inhibitor (CNI) based regimen. Nephrotoxicity is a common adverse effect of CNIs which can lead…2020 American Transplant Congress
Outcomes of Induction with T Lymphocyte-Depleting and IL-2 Receptor Blocking (IL-2RB) Antibodies in the Non-Broadly Sensitized Adult Deceased-Donor Kidney Transplant Recipients: Analysis in the Context of the CPRA Allocation System
*Purpose: We studied outcomes of induction in non-broadly-sensitized adult deceased-donor kidney transplant recipients(DD-KTRs) in the context of the calculated panel reactive antibody (CPRA) allocation system.*Methods:…2020 American Transplant Congress
Induction Therapy with Basiliximab versus Thymoglobulin in African-American Kidney Transplant Recipients in the Current Era of Immunosuppression
*Purpose: It is now common practice in the transplant community to select induction therapy on the basis of perceived immunological risk for acute rejection which…2020 American Transplant Congress
Renal Transplant Induction Therapy Safety Outcomes Comparison
*Purpose: Induction immunosuppression with alemtuzumab and rabbit anti-thymocyte globulin (r-ATG) reduces acute rejection following kidney transplantation. Efficacy is thought to be similar between the agents…2020 American Transplant Congress
Causal Relationship between Anti-Thymocyte Globulin Induction Therapy and Development of Monomorphic PTLD in Renal Transplant Recipients
*Purpose: The aim of our study is to explore the causality between ATG and different types of post-transplant lymphoproliferative disorder (PTLD) in renal transplant recipients…2019 American Transplant Congress
Allogenic Islets Cure Diabetes Following Transplantation in Omental Pouch in a Non-Human Primate Model
*Purpose: In the current standard clinical transplant approach, islet cells are administered intravenously into the portal system where they lodge in the liver. This approach…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 8
- Next Page »